Skip to main content

Table 1 Results for patients with PCR confirmed Plasmodium falciparum malaria at enrolment

From: Assessment of the therapeutic efficacy of artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in northern KwaZulu-Natal: an observational cohort study

Age Gender Travel 60 days prior to illness Temp mdr1copy number (lumefantrine sensitivity) mdr1N86Y gene (chloroquine sensitivity) Chloroquine resistance transporter genecrtK76T codons 72-76 Follow-up day Follow-upP. falciparummalaria PCR
40 Female Mozambique 36.5 1 Asparagine (mdr1 86N) CVMNK 28 Negative
7 Male Not recorded 39.4 1 asparagine CVMNK and CVIET 191 Negative
32 Female None 36.4 1 asparagine CVIET 168 Insufficient sample
24 Male None 39.3 1 asparagine CVMNK 49 Negative
9 Female Not recorded Not recorded 1 asparagine CVMNK 29 Negative
31 Male Mozambique 38.3 1 asparagine CVMNK 32 Negative
8 Female None 36.7 1 asparagine CVIET 29 Negative
15 Male Mozambique 38.0 1 asparagine CVIET 106 Negative
20 Male Mozambique 41.0 1 asparagine CVMNK 127 Negative
37 Female Not recorded 38.7 1 asparagine CVMNK 86 Negative
6 Female None 39.0 1 asparagine CVMNK 28 Negative
2 Female Mozambique Not recorded 1 asparagine CVMNK NA Lost to follow-up; returned to Mozambique
17 Male None 38.2 1 asparagine CVMNK 69 Negative
14 Female None 38.0 1 asparagine CVMNK 92 Negative
4 Female Mozambique 38.0 1 asparagine CVMNK 59 Negative
3 Male Not recorded 38.0 1 asparagine CVMNK 57 Negative